BPMUF News 108.5540 Basilea Pharmaceutic (BPMUF)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Basilea Pharmaceutic (BPMUF) 108.5540 $BPMUF

Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.
GlobeNewswire - Wed Apr 09, 11:44AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that at today's Ordinary General Meeting of Shareholders for the financial year 2013, shareholders approved all agenda items proposed by the Board of Directors. At the meeting, 51.3 percent of Basilea's share capital was represented.

Basilea's oncology drug candidate BAL101553 demonstrates broad antitumor activity in treatment-resistant breast cancer models as presented at AACR
GlobeNewswire - Mon Apr 07, 12:24AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that new data demonstrating the broad activity of Basilea's novel oncology drug candidate BAL101553 in pre-clinical models of human breast cancer, including models resistant to standard agents used for the treatment of breast cancer, were presented at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, California, USA.

Astellas Secures Exclusive Rights to Commercialize Isavuconazole in the U.S. and Canada
PR Newswire - Fri Feb 28, 6:00AM CST
Astellas Pharma Inc. (Tokyo:4503, "Astellas" announced today that the company has amended the License, Co-Development and Co-Promotion Agreement on isavuconazole under co-development with Basilea Pharmaceutica Ltd. ("Basilea" . Based on this amendment, the territories subject to the License Agreement have been changed to reflect that Astellas will be responsible for all regulatory filings and will exclusively commercialize and assume full responsibility for manufacturing isavuconazole in the U.S. and Canada.

Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America
GlobeNewswire - Fri Feb 28, 12:20AM CST
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the amendment as of February 27, 2014 of the isavuconazole License, Co-Development and Co-Promotion Agreement with Astellas Pharma Inc. originally executed in 2010, providing Basilea full rights to isavuconazole in all markets outside of the U.S. and Canada in return for Basilea's right to co-promote the product in the U.S. and Canada and its right to receive payments related to co-promotion and EU milestone payments.

Basilea reports that isavuconazole receives Qualified Infectious Disease Product designation from U.S. FDA for the treatment of invasive mucormycosis
GlobeNewswire - Thu Feb 27, 12:21AM CST
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as zygomycosis), a life-threatening invasive fungal infection caused by certain emerging molds.

Skin And Soft Tissue Infections - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 18, 2:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/njnc4s/skin_and_soft) has announced the addition of the "Skin And Soft Tissue Infections - Pipeline Review, H2 2013" report to their offering. 'Skin And Soft Tissue Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin And Soft Tissue Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Soft Tissue Infections. Scope - A snapshot of the global therapeutic scenario for Skin And Soft Tissue Infections. - A review of the Skin And Soft Tissue Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Skin And Soft Tissue Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Skin And Soft Tissue Infections Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Drug Profiles dalbavancin - Drug Profile ceftobiprole medocaril - Drug Profile AB-103 - Drug Profile levonadifloxacin - Drug Profile RX-04 - Drug Profile Gram Positive Antibiotic For SSTI And CAP - Drug Profile Featured News & Press Releases Appendix Companies Mentioned Wockhardt Limited Basilea Pharmaceutica AG Atox Bio Inc. Durata Therapeutics, Inc. Melinta Therapeutics Inc. Demuris Ltd. For more information visit http://www.researchandmarkets.com/research/nj...n_and_soft About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 03, 2:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fg3mhf/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013" report to their offering. 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Scope - A snapshot of the global therapeutic scenario for Hospital Acquired Pneumonia (HAP). - A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Cubist Pharmaceuticals, Inc. Basilea Pharmaceutica AG Aridis Pharmaceuticals LLC Tetraphase Pharmaceuticals Inc. Meiji Seika Pharma Co., Ltd. Biota Pharmaceuticals, Inc. Adenium Biotech ApS Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/fg...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Basilea reports that isavuconazole receives Qualified Infectious Disease Product (QIDP) designation from U.S. FDA for the treatment of invasive aspergillosis
GlobeNewswire - Tue Dec 03, 12:19AM CST
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis.

Inflammatory Bowel Disease - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/g29c7q/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2013" report to their offering. 'Inflammatory Bowel Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Scope - A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease. - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Introduction Inflammatory Bowel Disease Overview Therapeutics Development Companies Involved in Inflammatory Bowel Disease Therapeutics Development Inflammatory Bowel Disease - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned - 4SC - AlbireoPharma - Addex Pharmaceuticals - Basilea Pharmaceutica - Biotec Pharmacon - Compugen - Emergent BioSolutions - Eisai - Ferring Pharmaceuticals - GlaxoSmithKline - Indus Biotech Private Limited - Inotek Pharmaceuticals - Jenrin Discovery - Johnson & Johnson - KYORIN Pharmaceutical - Karo Bio - Lycera - Morria Biopharmaceuticals - Mitsubishi Tanabe Pharma - N30 Pharmaceuticals - Nephrx Corporation - Ono Pharmaceutical - Onyx Pharmaceuticals - PepTcell Limited - Paratek Pharmaceuticals - RaQualia Pharma - Rigel Pharmaceuticals - Santarus, Inc. - Synergy Pharmaceuticals - TiGenix NV - Upsher-Smith Laboratories - VentiRx Pharmaceuticals - Ventria Bioscience - Vitae Pharmaceuticals - Zealand Pharma A/S - iCo Therapeutics For more information visit http://www.researchandmarkets.com/research/g2...flammatory

Basilea reports isavuconazole orphan drug designation for treatment of zygomycosis by U.S. FDA
Thomson Reuters ONE - Mon Nov 18, 12:16AM CST
Basilea Pharmaceutica AG / Basilea reports isavuconazole orphan drug designation for treatment of zygomycosis by U.S. FDA . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Market Research: Gram-Positive Bacterial Infections - Pipeline Review, H2 2013
M2 - Wed Nov 06, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/lxgdwn/grampositive) has announced the addition of the "Gram-Positive Bacterial Infections - Pipeline Review, H2 2013" report to their offering. 'Gram-Positive Bacterial Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections. Scope - A snapshot of the global therapeutic scenario for Gram-Positive Bacterial Infections. - A review of the Gram-Positive Bacterial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gram-Positive Bacterial Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Rib-X Pharmaceuticals, Inc. Aphios Corporation BioMarin Pharmaceutical Inc. Alchemia Limited Immtech Pharmaceuticals, Inc. Basilea Pharmaceutica Ltd. Oragenics, Inc. Dongwha Pharm Co., Ltd. Theravance, Inc. Phynova Group Ltd Novabiotics Ltd Priaxon AG ConjuGon, Inc. MicuRx Pharmaceuticals, Inc. AiCuris GmbH & Co. KG Destiny Pharma Ltd. Atox Bio Inc. Microbiotix, Inc. Cellceutix Corporation KYORIN Pharmaceutical Co., Ltd. Lytix Biopharma AS TAXIS Pharmaceuticals, Inc. Aureogen Biosciences, Inc. Cantab Biopharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/lx...ampositive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market to 2016: Pfizer, Cubist, ViroPharma, Forest Labs Dominate
M2 - Tue Nov 05, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/nptv4k/global) has announced the addition of the "Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market to 2016" report to their offering. The Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market to grow at a CAGR of 3 percent over the period 2012-2016. The most common trend witnessed in the Global MRSA Drugs market is various governmental and non-governmental awareness programs that are informing people about the advanced treatments and educating people about the spread of infections. Moreover, vendors are supporting such comprehensive care programs through awareness campaigns for educating people about the spread and the treatment of infectious diseases.' According to the report, the increase in the prevalence of MRSA infections has increased the usage of drugs used against MRSA infection across the globe. Further, the report states that the rapid development of resistance to existing therapies is a major factor hampering the growth of the Global MRSA Drugs market. The key vendors dominating this market space are: - Pfizer Inc. - Cubist Pharmaceuticals Inc. - ViroPharma Inc. - Theravance Inc. - Forest Laboratories Inc. The other vendors mentioned in the report are: - Basilea Pharmaceutica Ltd. - Durata Therapeutics, Inc. - Novartis AG - Trius Therapeutics, Inc. - AstraZeneca plc. - GlaxoSmithKline plc. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Five Force Analysis 8. Geographical Segmentation 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/nptv4k/global

Breast Cancer - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Breast Cancer
M2 - Tue Nov 05, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfkggb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Breast Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. Breast Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Breast Cancer. - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Breast Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some of the Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Kyowa Hakko Kirin Co., Ltd. - Celsion Corporation - Biogen Idec Inc. - Amgen Inc. - A&G Pharmaceutical, Inc. - Novartis AG - Aphios Corporation - Biocon Limited - Chong Kun Dang Pharmaceutical - Marshall Edwards, Inc. - Basilea Pharmaceutica Ltd. - Bionomics Limited - MultiCell Technologies, Inc. - Neuren Pharmaceuticals Limited - Natco Pharma Limited - Sareum Holdings plc - TRACON Pharmaceuticals, Inc. - Nexgenix Pharmaceuticals, LLC - DEKK-TEC, Inc. - Regulon Inc. - AUS Bio Limited - EirGen Pharma Ltd. - Epeius Biotechnologies Corporation - Ampio Pharmaceuticals, Inc. - CytomX, LLC. For more information visit http://www.researchandmarkets.com/research/hf...ast_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Basilea appoints new Chief Financial Officer
Thomson Reuters ONE - Mon Nov 04, 12:15AM CST
Basilea Pharmaceutica AG / Basilea appoints new Chief Financial Officer . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Basilea's antibiotic ceftobiprole obtains regulatory approval in Europe for pneumonia
Thomson Reuters ONE - Wed Oct 23, 12:16AM CDT
Basilea Pharmaceutica AG / Basilea's antibiotic ceftobiprole obtains regulatory approval in Europe for pneumonia . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 91

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 58

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
SoCalGas Data Program Puts Metering Case Into Focus

Updated Category News Views 61

Buried beneath the usual utility-company polish is a pretty sensible idea: find waste before a customer gets walloped by a bill. SoCalGas says its Advanced Meter Analytics program has helped customers avoid an estimated $11 million in unnecessary natural-gas costs since 2019. That is not a number likely to move Sempra’s earnings by itself, and nobody should pretend...

Continue Reading
Perigon Builds Its Investment Bench for the Next Leg

Updated Category News Views 110

Perigon is rearranging the engine room before the next growth spurt gets noisy. The firm has named Christopher Broderick Director of Investments and Research, added two trading associates, and put another brick behind the broader operating structure Rafia Hasan has been assembling since taking on the chief operating officer role in August. That may sound like ordinary...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 87

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 247

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 27

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 95

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
San Bernardino Teamsters Back Their Historic Contract

Updated Category News Views 61

A 90% vote does not whisper; it rattles the filing cabinets. More than 12,000 San Bernardino County members of Teamsters Local 1932 have ratified a new labor agreement with over 90% approval, according to the union’s November 20 announcement. In a public-sector negotiation, that kind of margin matters because it tells management the workforce is not merely accepting a...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 64

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Jaw Clicking and TMJ: Expert Advice

Updated Category News Views 43

An Unseen Complication: The Problem with Jaw Clicking When something's wrong, especially with the body's mechanics, there's usually a sound telling you so. Hearing a click every time you chew? Dr. Georgia Knotek from Greenfield knows all about it. In a recent HelloNation article, she dives into this unsettling symptom that many shrug off but shouldn't. Let's talk about...

Continue Reading
Aduro Clean Technologies Expands Leadership and Marketing Initiatives

Updated Category News Views 149

Aduro Clean Technologies Enhances Leadership and Marketing Strategies Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (NASDAQ: ADUR), has made significant strides in its journey towards commercialization. The Company, which specializes in clean technology to recycle lower-value feedstocks like waste plastics and heavy bitumen, is strengthening its team as...

Continue Reading
Katahdin Bankshares Corp. Reveals Increased Dividend Payment

Updated Category News Views 145

Katahdin Bankshares Corp. Declares Fourth Quarter Dividend Katahdin Bankshares Corp. (OTCQX: KTHN), the parent company of Katahdin Trust Company, recently announced an exciting update regarding its quarterly dividend. In an effort to reward its loyal shareholders, the company has declared a cash dividend of $0.2025 per share for the fourth quarter. This payment is...

Continue Reading
Symbotic Inc. Faces Class Action Lawsuit Amid Investor Losses

Updated Category News Views 336

Class Action Lawsuit Filed Against Symbotic Inc. In recent developments, a law firm recognized nationally, Bronstein, Gewirtz & Grossman, LLC, has taken a significant step by notifying investors about a class action lawsuit involving Symbotic Inc. (NASDAQ: SYM). This legal action targets certain officers of the company while focusing on protecting the interests of...

Continue Reading
Persona-Triangle Welcomes Arron Yount as Its New CEO

Updated Category News Views 156

Persona-Triangle Appoints Arron Yount as CEO Persona-Triangle recently announced the appointment of Arron B. Yount as its new Chief Executive Officer. With a robust background in operations and a history of enhancing multi-divisional businesses, Yount is expected to lead the company into a new chapter of growth and innovation. Leadership Experience Driving Change Bringing...

Continue Reading